PDF(Pubmed)
Abstract：
UNASSIGNED: Hepatocellular carcinoma (HCC) accounts for approximately 90% of primary liver cancer and can be caused by well-known risk factors, including infection with hepatitis B and C viruses, alcohol intake, and metabolic syndrome. The overall prognosis remains poor with a median survival of 1 year for symptomatic advanced-stage cases treated with systemic therapies.
UNASSIGNED: In July 2020, a 73-year-old male patient presented at our institution with mild abdominal pain and an attack of intense cold. After a radiological workup, the diagnosis of HCC located in the caudate lobe was established. The patient underwent atypical caudate lobe resection, and pathology confirmed the diagnosis of grade 3 HCC. Postoperative MRI showed a new metastasis in the 6th liver segment 1.3 cm in diameter, and a PVT progression which now affected the whole right lobe. The patient was started on sorafenib and demonstrated a complete response which still lasts for more than two years.
UNASSIGNED: We present a rare case of a patient who demonstrated a complete response to sorafenib treatment in advanced HCC with unfavorable prognostic factors.
UNASSIGNED: In July 2020, a 73-year-old male patient presented at our institution with mild abdominal pain and an attack of intense cold. After a radiological workup, the diagnosis of HCC located in the caudate lobe was established. The patient underwent atypical caudate lobe resection, and pathology confirmed the diagnosis of grade 3 HCC. Postoperative MRI showed a new metastasis in the 6th liver segment 1.3 cm in diameter, and a PVT progression which now affected the whole right lobe. The patient was started on sorafenib and demonstrated a complete response which still lasts for more than two years.
UNASSIGNED: We present a rare case of a patient who demonstrated a complete response to sorafenib treatment in advanced HCC with unfavorable prognostic factors.
摘要：
■肝细胞癌（HCC）约占原发性肝癌的90％，可由众所周知的危险因素引起，包括感染乙型肝炎和丙型肝炎病毒，酒精摄入量,和代谢综合征。全身疗法治疗的有症状的晚期病例的总体预后仍然较差，中位生存期为1年。
2020年7月，一名73岁的男性患者在我们机构就诊，患有轻度腹痛和强烈感冒。经过放射检查,确定了位于尾状叶的HCC的诊断。患者接受了非典型尾状叶切除术，病理证实诊断为3级肝癌。术后MRI显示直径1.3cm的第6段肝新转移，和PVT进展，现在影响了整个右叶。患者开始服用索拉非尼，并表现出完全反应，仍持续两年以上。
■我们介绍了一例罕见的患者，该患者对索拉非尼治疗在晚期HCC中表现出完全反应，并具有不良预后因素。
2020年7月，一名73岁的男性患者在我们机构就诊，患有轻度腹痛和强烈感冒。经过放射检查,确定了位于尾状叶的HCC的诊断。患者接受了非典型尾状叶切除术，病理证实诊断为3级肝癌。术后MRI显示直径1.3cm的第6段肝新转移，和PVT进展，现在影响了整个右叶。患者开始服用索拉非尼，并表现出完全反应，仍持续两年以上。
■我们介绍了一例罕见的患者，该患者对索拉非尼治疗在晚期HCC中表现出完全反应，并具有不良预后因素。
